Loading page…

Report overview

The report presents Envision Pharma Group's 2023 sustainability performance, including a 53% reduction in Scope 1 and 2 emissions from its 2019 baseline and a 2023 market-based emissions inventory totaling 14,645 tCO2e. It describes a first double materiality assessment that informed the company's sustainability strategy. The company also reports a CDP climate action B rating, UN Global Compact participation, and reporting in accordance with GRI Standards.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language
Pages
File size

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status
CDP score

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Employees
Women on the board

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services